Skip to main content
SpringerLink
Log in

Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Medroxyprogesterone acetate (MPA) is a synthetic progestin, currently used in the adjuvant treatment of advanced breast cancer, which induces remission rates (30–40%) comparable to those obtained with other types of endocrine therapies. Since, in addition to its progestin-like action, MPA exhibits androgen- and glucocorticoid-like activities in other tissues, the present study was designed to assess the relative contribution of the different steroid receptor systems in the direct action of MPA on breast cancer cell growth, using the ZR-75-1 human mammary carcinoma cell line as anin vitro model.

Unlike pure progestins, MPA potently inhibited the proliferation of ZR-75-1 cells in a concentrationdependent manner either in the presence or in the absence of estrogens, and the addition of insulin had only marginal effects on its growth-inhibitory activity. On the other hand, both hydroxyflutamide (OHF, a non-steroidal monospecific antiandrogen) and RU486 (a potent antiglucocorticoid and antiprogestin also endowed with antiandrogenic activity) competitively reversed MPA antiproliferative effects. MPA further decreased the growth of ZR-75-1 cells co-incubated with maximally inhibitory concentrations of either 5α-dihydrotestosterone (DHT) or dexamethasone (DEX), although at about 300-fold higher MPA concentrations with DHT-treated than with DEX-treated ZR-75-1 cells, thus demonstrating a highly predominant androgenic effect. However, MPA had no effect on the growth of ZR-75-1 cells co-incubated with DHT and DEX simultaneously, thus supporting the predominant role of androgen and glucocorticoid receptors in MPA action. A 12-day preincubation of ZR-75-1 cells with increasing concentrations of MPA (10−12 to 3 × 10−6M) decreased the specific uptake of [3H]estradiol (E2) by intact cell monolayers to the same extent as 10 nM DHT, an effect which was competitively blocked by the addition of OHF (3 µM). MPA action on ZR-75-1 cell growth also significantly differed from that of progestins in being additive to the inhibition of E2-stimulated growth by the steroidal antiestrogen ICI164384.

The present data indicate that the main action of MPA on ZR-75-1 human breast cancer cell growth is due to its androgen receptor-mediated inhibitory action, while its glucocorticoid-like activity could play an additional role at high concentrations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mattsson W: Current status of high dose progestin treatment in advanced breast cancer. Breast Cancer Res Treat 3: 231–235, 1983

    PubMed  Google Scholar 

  2. Blumenschein GR: The role of progestins in the treatment of breast cancer. Semin Oncol 10: 7–10, 1983 (suppl.)

    Google Scholar 

  3. Hortobagyi GN, Buzdar AU, Frye D, Yap HY, Hug V, Pinnamaneni K, Fraschini G, Halvorson HC, Blumenschein GR: Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat 5: 321–326, 1985

    PubMed  Google Scholar 

  4. Haller DG, Glick JH: Progestational agents in advanced breast cancer: an overview. Semin Oncol 13: 2–8, 1986 (suppl.)

    PubMed  Google Scholar 

  5. Horwitz KB: The structure and function of progesterone receptors in breast cancer. J Steroid Biochem 27: 447–457, 1987

    PubMed  Google Scholar 

  6. Lippman ME: Antiestrogen therapy of breast cancer. Semin Oncol 10: 11–19, 1983 (suppl.)

    PubMed  Google Scholar 

  7. Perez-Palacios G, Chavez B, Vilchis F, Escobar N, Larrea F, Perez AE: Interaction of medroxyprogesterone acetate with cytosol androgen receptors in the rat hypothalamus and pituitary. J Steroid Biochem 19: 1729–1735, 1983

    PubMed  Google Scholar 

  8. Jänne OA, Bardin CW: Steroid receptors and hormone action: physiological and synthetic androgens and progestins can mediate inappropriate biological effects. Pharmacol Rev 36: 35S-42S, 1984

    PubMed  Google Scholar 

  9. Pridjian G, Schmit V, Schreiber J: Medroxyprogesterone acetate: receptor binding and correlated effects on steroidogenesis in rat granulosa cells. J Steroid Biochem 26: 313–319, 1987

    PubMed  Google Scholar 

  10. Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP: Towards the mapping of the progesterone receptor. J Steroid Biochem 27: 255–269, 1987

    PubMed  Google Scholar 

  11. Teulings FAG, van Gilse HA, Henkelman MS, Portengen H, Alexieva-Figusch J: Estrogen, androgen, glucocorticoid and progesterone receptors in progestin-induced regression of human breast cancer. Cancer Res 40: 2557–2561, 1980

    PubMed  Google Scholar 

  12. Young PCM, Keen FK, Einhorn LH, Stanick BM, Ehrlich CE, Cleary RE: Binding of medroxyprogesterone acetate in human breast cancer. Am J Obstet Gynecol 137: 284–292, 1980

    PubMed  Google Scholar 

  13. Bullock LP, Bardin CW, Sherman MR: Androgenic, antiandrogenic and synandrogenic actions of progestins: role of steric and allosteric interactions with androgen receptors. Endocrinology 103: 1768–1782, 1978

    PubMed  Google Scholar 

  14. Blossey HC, Wander HE, Koebberling J, Nagel GA: Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 54: 1208–1215, 1984

    PubMed  Google Scholar 

  15. Van Veelen H, Willemse PHB, Sleijfer DT, van der Ploeg E, Sluiter WJ, Doorenbos H: Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients. Cancer Chemother Pharmacol 15: 167–170, 1985

    PubMed  Google Scholar 

  16. Van Veelen H, Willemse PH, Sleijfer DT, Sluiter WJ, Doorenbos H: Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer. Cancer Treat Rep 69: 977–983, 1985

    PubMed  Google Scholar 

  17. Labrie F, Ferland L, Lagacé L, Drouin J, Asselin J, Azadian-Boulanger G, Raynaud JP: High inhibitory activity of R5020, a pure progestin, at the hypothalamic-adenohypophyseal level on gonadotropin secretion. Fertil Steril 28: 1104–1112, 1977

    PubMed  Google Scholar 

  18. Perez-Palacios G, Chavez B, Escobar N, Vilchis F, Larrea F, Lince M, Perez AE: Mechanism of action of contraceptive synthetic progestins. J Steroid Biochem 15: 125–130, 1981

    PubMed  Google Scholar 

  19. Lelli G, Angelleli B, Zanichelli L: The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patients. Chemiotherapia 3: 327–329, 1984

    Google Scholar 

  20. Labrie C, Cusan L, Plante M, Lapointe S, Labrie F: Analysis of the androgenic activity of synthetic ‘progestins’ currently used for the treatment of prostate cancer. J Steroid Biochem 28: 379–384, 1987

    PubMed  Google Scholar 

  21. Iacobelli S, Sica G, Natoli C, Gatti D: Inhibitory effects of medroxyprogesterone acetate on the proliferation of human breast cancer cells. In: Campio L, Robustelli Della Cuna G, Taylor CW (eds) Role of Medroxyprogesterone in Endocrine-Related Tumors, Vol. 2. Raven Press, New York, 1983, pp 1–6

    Google Scholar 

  22. Allegra JC, Kiefer SM: Mechanisms of action of progestational agents. Semin Oncol 12: 3–5, 1985 (suppl.)

    PubMed  Google Scholar 

  23. Wittliff JL: Steroid-hormone receptors in breast cancer. Cancer 53: 630–643, 1984

    PubMed  Google Scholar 

  24. Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HMT, Aitken SC: Distribution, frequency and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 39: 1447–1454, 1979

    PubMed  Google Scholar 

  25. Horwitz KB, Zava DT, Thilagar AK, Jensen EM, McGuire WL: Steroid receptor analyses of nine human breast cancer cell lines. Cancer Res 38: 2434–2437, 1978

    PubMed  Google Scholar 

  26. Ojasoo T, Raynaud JP: Receptor binding profiles of progestins. IN: Jasonni VM, Nenci I, Flamigni C (eds) Steroids and Endometrial Cancer. Raven Press, New York, 1983, pp 1–28

    Google Scholar 

  27. Engel LW, Young NA, Trolka TS, Lippman ME, O'Brien SJ, Joyce MY: Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 38: 3352–3364, 1978

    PubMed  Google Scholar 

  28. Darbre P, Yates J, Curtis S, King RJB: Effect of estradiol on human breast cancer cells in culture. Cancer Res 43: 349–354, 1983

    PubMed  Google Scholar 

  29. Poulin R, Labrie F: Stimulation of cell proliferation and estrogenic response by adrenal C19—D5 steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46: 4933–4937, 1986

    PubMed  Google Scholar 

  30. Poulin R, Baker D, Labrie F: Potent inhibition of basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 12: 213–225

  31. Osborne CK, Monaco ME, Kahn CR, Huff K, Bronzert D, Lippman ME: Direct inhibition of growth and antagonism by glucocorticoids in human breast cancer cells in culture. Cancer Res 39: 2422–2428, 1979

    PubMed  Google Scholar 

  32. Poulin R, Poirier D, Labrie F: Specific inhibition of cell proliferation by progestins and its antagonism by insulin in the ZR-75-1 human breast cancer cell line. 24th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 1988, Abstract 151

  33. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83: 2496–2500, 1986

    PubMed  Google Scholar 

  34. Taylor CM, Blanchard B, Zava DT: A simple method to determine whole-cell uptake of radiolabelled oestrogen and progesterone and their subcellular localization in breast cancer cell lines in monolayer culture. J Steroid Biochem 20: 1083–1088, 1984

    PubMed  Google Scholar 

  35. Wakeling AE, Bowler J: Steroidal pure antiestrogens. J Endocrinol 112: R7-R10, 1987

    PubMed  Google Scholar 

  36. Gagné D, Pons M, Philibert D: RU38486: a potent antiglucocorticoidin vitro andin vivo. J Steroid Biochem 23: 247–251, 1985

    PubMed  Google Scholar 

  37. Horwitz KB: The antiprogestin RU38486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells. Endocrinology 116: 2236–2245, 1985

    PubMed  Google Scholar 

  38. Raynaud JP, Ojasoo T: The design and use of sex-steroid antagonists. J Steroid Biochem 25: 811–833, 1986

    PubMed  Google Scholar 

  39. Simard J, Luthy I, Guay J, Bélanger A, Labrie F: Characteristics of the interaction of the antiandrogen Flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 44: 261–270, 1986

    PubMed  Google Scholar 

  40. Rodbard D: Apparent cooperative effect in cyclic AMP and corticosterone production by isolated adrenal cells in response to ACTH analogues. Endocrinology 94: 1427–1437, 1974

    PubMed  Google Scholar 

  41. Cheng Y, Prusoff WH: Relationship between the inhibition constant (Ki) and the concentration of inhibition which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22: 3099–3108, 1973

    PubMed  Google Scholar 

  42. Philibert D: RU38486: an original multifaceted antihormonein vivo. In: Agarwal MK (ed) Adrenal Steroid Antagonism. Walter de Guyter, Berlin (1984) pp 77–101

    Google Scholar 

  43. Poulin R: Androgens suppress immunologically detectable estrogen and progesterone receptors in ZR-75-1 human breast cancer cells. 70th Annual Meeting of the Endocrine Society, New Orleans, LA, (Abstract), p 347, 1988

  44. Gill PG, Vignon F, Bardon S, Derocq D, Rochefort H: Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells. Breast Cancer Res Treat 10: 37–45, 1987

    PubMed  Google Scholar 

  45. Ip MM, Milholland RJ, Kim U, Rosen F: Androgen control of cytosol progesterone receptor levels in the MT-W9B transplantable mammary tumors in the rat. J Natl Cancer Inst 69: 673–681, 1982

    PubMed  Google Scholar 

  46. MacIndoe JH, Etre LA: An antiestrogenic action of androgens in human breast cancer cells. J Clin Endocrinol Metab 53: 836–842, 1981

    PubMed  Google Scholar 

  47. Wei LL, Krett NL, Francis MD, Gordon DF, Wood WM, O'Malley BW, Horwitz KB: Multiple human progesterone receptor messenger ribonucleic acids and their autoregulation by progestin agonists and antagonists in breast cancer cells. Mol Endocrinol 2: 62–72, 1988

    PubMed  Google Scholar 

  48. Read LD, Snider CE, Miller JS, Greene GL, Katzenellenbogen BS: Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol Endocrinol 2: 263–271, 1988

    PubMed  Google Scholar 

  49. Raynaud JP, Ojasoo T, Pottier J: Chemical substitution of steroid hormones: effect on receptor binding and pharmacokinetics. In: Litwack G (ed) Biochemical Actions of Hormones, Vol. IX. Academic Press, New York, 1982, pp. 305–342

    Google Scholar 

  50. Moguilewsky M, Deraedt R: Interrelations between glucocorticoid and progestin receptors. J Steroid Biochem 15: 329–335, 1981

    PubMed  Google Scholar 

  51. Di Carlo F, Racca S, Conti G, Gallo E, Muccioli G, Sapino A, Bussolati G: Effects of long-term administration of high doses of medroxyprogesterone acetate on hormone receptors and target organs on the female rat. J Endocrinol 103: 287–293, 1984

    PubMed  Google Scholar 

  52. Raynaud JP, Ojasoo T, Labrie F: Steroid hormones-agonists and antagonists. In: Lewis GP, Ginsburg M (eds) Mechanisms of Steroid Action. MacMillan Press, London, 1981, pp 145–158

    Google Scholar 

  53. Guthrie GP, John WJ: Thein vivo glucocorticoid and antiglucocorticoid actions of medroxyprogesterone acetate. Endocrinology 107: 1393–1396, 1980

    PubMed  Google Scholar 

  54. McGuire WL, Clark GM: The prognostic role of progesterone receptors in human breast cancer. Semin Oncol 10: 2–6, 1983

    Google Scholar 

  55. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer 54: 2436–2440, 1984

    PubMed  Google Scholar 

  56. Horwitz KB, Freidenberg GR: Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47Dco human breast cancer cells by progestins: implications for endocrine therapies. Cancer Res 45: 167–173, 1985

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MRC Group in Molecular Endocrinology, CHUL Research Center, Laval University Medical Center, 2705 Boulevard Laurier, G1V 4G2, Sainte-Foy, Québec, Canada

    Richard Poulin, Denis Baker, Donald Poirier & Fernand Labrie

Authors
  1. Richard Poulin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Denis Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donald Poirier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fernand Labrie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poulin, R., Baker, D., Poirier, D. et al. Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res Tr 13, 161–172 (1989). https://doi.org/10.1007/BF01806528

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806528

Key words

Search

Navigation